Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

XTANDI™ (Enzalutamide) Authorized in the European Union for Advanced Prostate Cancer



  XTANDI™ (Enzalutamide) Authorized in the European Union for Advanced
  Prostate Cancer

  --Enzalutamide authorized in European Union for the treatment of adult men
    with metastatic castration-resistant prostate cancer whose disease has
                  progressed on or after docetaxel therapy--

Business Wire

CHERTSEY, England & SAN FRANCISCO -- June 24, 2013

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas
Pharma Inc. (TSE:4503), and Medivation, Inc. (Nasdaq: MDVN) announced that
following the regulatory review process by the European Medicines Agency (EMA)
and a positive opinion from the Committee for Medicinal Products for Human Use
on April 25, 2013, the European Commission (EC) has granted the marketing
authorization for XTANDI^™ (enzalutamide) capsules for the treatment of adult
men with metastatic castration-resistant prostate cancer whose disease has
progressed on or after docetaxel therapy.

“This is a major development in prostate cancer therapeutics that will provide
an important new treatment option for patients with advanced prostate cancer
following chemotherapy,” said Professor Johann de Bono, Professor of
Experimental Cancer Medicine at The Institute of Cancer Research, London, and
Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

Professor de Bono, who is also Head of the Drug Development Unit, a joint
facility between The Royal Marsden NHS Foundation Trust and The Institute of
Cancer Research, located at The Royal Marsden, added: “Enzalutamide, an oral
drug, improves the quality of life and survival time for patients who have an
advanced form of this common disease and is generally well tolerated.”

The EC grant of the marketing authorization applies in all European Union (EU)
Member States, as well as in the European Economic Area (EEA) countries
Iceland, Liechtenstein and Norway.

Dr. Erik Briers, Executive Director, European Cancer Patient Coalition (ECPC)
and member of the strategic committee of Europa Uomo  comments: “Unfortunately
prostate cancer can evolve into a life threatening castration resistant
metastatic condition where treatment options are needed because all patients
are not identical. A new treatment such as enzalutamide is one more option
that will give selected patients a new chance if other options fail. Patients
with advanced prostate cancer are very concerned about their quality of life,
so they favor treatments with fewer side effects. Enzalutamide has been shown
to be generally well tolerated.”

The European Commission approval triggers a $15 million milestone payment to
Medivation under its collaboration with Astellas, which is reflected in
Astellas’ current fiscal year (from 1^st April 2013 to 31^st March 2014)
financial forecast.

About Enzalutamide

Enzalutamide is a novel, once-daily, oral androgen receptor inhibitor. It
inhibits multiple steps in the androgen receptor (AR) signaling pathway, which
has been shown preclinically to decrease cancer cell growth and can induce
cancer cell death (apoptosis).

The EU approval is based on results from the Phase 3 AFFIRM study which
confirmed that enzalutamide demonstrated a statistically significant
improvement (p < 0.0001) in overall survival compared to placebo, with a
median survival of 18.4 months in the enzalutamide group versus 13.6 months in
the placebo group, an advantage of 4.8 months [hazard ratio (HR) = 0.631]. The
study also concluded that enzalutamide was generally well tolerated by
patients and met all secondary endpoints. The Phase 3 AFFIRM trial was a
randomized, double-blind, placebo-controlled, multinational trial evaluating
enzalutamide (160 mg/day) versus placebo in 1,199 men with progressive
metastatic castration-resistant prostate cancer who were previously treated
with docetaxel-based chemotherapy.

Enzalutamide was approved by the U.S. Food and Drug Administration on August
31, 2012 for the treatment of patients with metastatic castration-resistant
prostate cancer (mCRPC) who have previously received docetaxel (chemotherapy)
and launched in the U.S. in September 2012. On May 30, 2013, Health Canada
approved XTANDI (enzalutamide) capsules for the treatment of patients with
metastatic castration-resistant prostate cancer in the setting of medical or
surgical castration who have received docetaxel therapy. Marketing
applications for XTANDI have also been submitted in Australia, Brazil, Japan,
South Korea, Switzerland and Brazil.

Advanced prostate cancer is defined as cancer that has spread outside of the
prostate to other areas of the body (metastasized). A high number of men with
advanced prostate cancer eventually develop a resistance to androgen
deprivation treatment, which is called castration-resistant prostate cancer
(CRPC). Around 10-20% of patients with prostate cancer present at an advanced
state, and up to 40% of men diagnosed with prostate cancer will eventually
develop advanced disease.

Important US Label Safety Information for XTANDI

Contraindications- XTANDI can cause fetal harm when administered to a pregnant
woman based on its mechanism of action. XTANDI is not indicated for use in
women. XTANDI is contraindicated in women who are or may become pregnant.

Warnings and Precautions- In the randomized clinical trial, seizure occurred
in 0.9% of patients on XTANDI. No patients on the placebo arm experienced
seizure. Patients experiencing a seizure were permanently discontinued from
therapy. All seizures resolved.

Patients with a history of seizure, taking medications known to decrease the
seizure threshold, or with other risk factors for seizure were excluded from
the clinical trial. Because of the risk of seizure associated with XTANDI use,
patients should be advised of the risk of engaging in any activity where
sudden loss of consciousness could cause serious harm to themselves or others.

Adverse Reactions- The most common adverse drug reactions ( ≥ 5%) reported in
patients receiving XTANDI in the randomized clinical trial were
asthenia/fatigue, back pain, diarrhea, arthralgia, hot flush, peripheral
edema, musculoskeletal pain, headache, upper respiratory infection, muscular
weakness, dizziness, insomnia, lower respiratory infection, spinal cord
compression and cauda equina syndrome, hematuria, paresthesia, anxiety, and
hypertension. Grade 1-4 neutropenia occurred in 15% of XTANDI patients (1%
Grade 3-4) and in 6% on placebo (no Grade 3-4). Grade 1-4 elevations in
bilirubin occurred in 3% of XTANDI patients and 2% on placebo. One percent of
XTANDI patients compared to 0.3% on placebo died from infections or sepsis.
Falls or injuries related to falls occurred in 4.6% of XTANDI patients vs 1.3%
on placebo. Falls were not associated with loss of consciousness or seizure.
Fall-related injuries were more severe in XTANDI patients and included
non-pathologic fractures, joint injuries, and hematomas. Grade 1 or 2
hallucinations occurred in 1.6% of XTANDI patients and 0.3% on placebo, with
the majority on opioid-containing medications at the time of the event.

Drug Interactions- Effect of Other Drugs on XTANDI: Administration of strong
CYP2C8 inhibitors can increase the plasma exposure to XTANDI.
Co-administration of XTANDI with strong CYP2C8 inhibitors should be avoided if
possible. If co-administration of XTANDI cannot be avoided, reduce the dose of
XTANDI. Co-administration of XTANDI with strong or moderate CYP3A4 and CYP2C8
inducers can alter the plasma exposure of XTANDI and should be avoided if
possible.

Effect of XTANDI on Other Drugs: XTANDI is a strong CYP3A4 inducer and a
moderate CYP2C9 and CYP2C19 inducer in humans. Avoid CYP3A4, CYP2C9 and
CYP2C19 substrates with a narrow therapeutic index, as XTANDI may decrease the
plasma exposures of these drugs. If XTANDI is co-administered with warfarin
(CYP2C9 substrate), conduct additional INR monitoring.

For Full Prescribing Information, please visit www.XtandiHCP.com.

About Astellas Pharma Europe

Astellas Pharma Europe Ltd., located in the UK, is the European Headquarters
of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company
dedicated to improving the health of people around the world through the
provision of innovative and reliable pharmaceuticals. As a global company,
Astellas is committed to combining outstanding research and development (R&D)
and marketing capabilities to continue to grow in the world pharmaceutical
market. Astellas Pharma Europe Ltd. manages 21 affiliate offices located
across Europe, the Middle East and Africa. In addition, the Company has an R&D
site and three manufacturing plants in Europe. The company employs
approximately 4,300 staff across these regions. For more information about
Astellas Pharma Europe, please visit http://www.astellas.eu.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which there are
limited treatment options. Medivation aims to transform the treatment of these
diseases and offer hope to critically ill patients and their families. For
more information, please visit us at www.medivation.com.

This press release contains forward-looking statements that are made pursuant
to the safe harbor provisions of the federal securities laws, including
statements regarding the expected commercialization of XTANDI. Any statements
contained in this press release that are not statements of historical fact may
be deemed to be forward-looking statements. Forward-looking statements involve
risks and uncertainties that could cause Medivation's actual results to differ
significantly from those projected, including, without limitation, the risk
that unanticipated developments could delay or prevent the launch and
commercialization of XTANDI, as well as other risks detailed in Medivation's
filings with the Securities and Exchange Commission, including its quarterly
report on Form 10-Q for the quarter ended March 31, 2013, filed on May 10,
2013 with the SEC. You are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date of this release.
Medivation disclaims any obligation or undertaking to update or revise any
forward-looking statements contained in this press release.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130623005059/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50657817&lang=en

Contact:

Medivation Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
or
Anne Bowdidge
Senior Director, Investor Relations
(650) 218-6900
or
Astellas Contacts:
Jenny Kite
Corporate Communications
(847) 682-4530
or
Mike Beyer
Sam Brown Inc. (media for both companies)
(773) 463-4211
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement